| 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) |
266 |
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
242 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic |
201 |
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
138 |
| Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists |
136 |
| Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up |
133 |
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer |
122 |
| Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 |
104 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
104 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry |
102 |
| ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease |
97 |
| Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases |
96 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
95 |
| Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study |
94 |
| Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 |
89 |
| Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study |
81 |
| Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 |
80 |
| Comprehensive analysis of the clinical immuno-oncology landscape |
79 |
| Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS |
77 |
| Updated results from MONALEESA- a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer |
72 |
| Novel patterns of response under immunotherapy |
70 |
| Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study |
68 |
| Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines |
68 |
| Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer |
65 |
| Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors |
65 |
| Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma |
63 |
| Selective RET kinase inhibition for patients with RET-altered cancers |
63 |
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer |
61 |
| A decade of clinical development of PARP inhibitors in perspective |
60 |
| ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach |
57 |
| Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |
57 |
| Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up |
56 |
| A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study |
56 |
| Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers |
54 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer |
53 |
| European cancer mortality predictions for the year 2019 with focus on breast cancer |
53 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) |
52 |
| Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program |
50 |
| European cancer mortality predictions for the year 2018 with focus on colorectal cancer |
50 |
| Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series |
50 |
| Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy |
49 |
| Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer |
48 |
| Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial |
47 |
| Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer |
47 |
| Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer |
46 |
| Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 |
46 |
| Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
45 |
| Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
45 |
| Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board |
45 |
| Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis |
45 |
| ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research |
44 |
| Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) |
44 |
| ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up |
44 |
| PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers |
42 |
| Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer |
42 |
| Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study |
42 |
| Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials |
42 |
| Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study |
41 |
| FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma |
41 |
| Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up |
40 |
| A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) |
40 |
| Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression |
40 |
| EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer |
39 |
| Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis |
39 |
| Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer |
38 |
| Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing |
37 |
| Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib |
37 |
| Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy |
37 |
| HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib |
36 |
| How liquid biopsies can change clinical practice in oncology |
35 |
| Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol |
35 |
| Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
35 |
| Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
34 |
| Immunological differences between primary and metastatic breast cancer |
34 |
| Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors |
34 |
| Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients |
34 |
| Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study |
33 |
| Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma |
33 |
| Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma |
32 |
| Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial |
32 |
| Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy |
31 |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS |
31 |
| Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer |
31 |
| Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto |
31 |
| Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? |
31 |
| Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge |
30 |
| Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy |
30 |
| Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS |
30 |
| The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? |
30 |
| European Society for Medical Oncology (ESMO) position paper on supportive and palliative care |
30 |
| Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study |
30 |
| TRK inhibitors in TRK fusion-positive cancers |
29 |
| Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer |
29 |
| Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial |
29 |
| Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study |
29 |
| First-in-human study of LY303 an oral Notch signaling inhibitor in advanced or metastatic cancer |
29 |
| Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study |
28 |
| Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) |
28 |
| OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer |
27 |
| Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials |
27 |
| Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy |
27 |
| Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma |
27 |
| The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial |
26 |
| Safety and dose modification for patients receiving niraparib |
26 |
| Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer |
26 |
| CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials |
26 |
| Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma |
26 |
| Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
25 |
| Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer |
25 |
| Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial |
25 |
| Surgery in reference centers improves survival of sarcoma patients: a nationwide study |
25 |
| Optimizing panel-based tumor mutational burden (TMB) measurement |
24 |
| Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies |
24 |
| Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study |
24 |
| Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206 |
24 |
| Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium |
24 |
| Identifying patients with NTRK fusion cancer |
23 |
| Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial |
23 |
| A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma |
23 |
| Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial |
23 |
| A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02) |
23 |
| Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
22 |
| Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines |
22 |
| Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer |
22 |
| How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer |
22 |
| Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer |
22 |
| Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer |
22 |
| Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group |
22 |
| Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
22 |
| Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms |
21 |
| Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer |
21 |
| RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study |
21 |
| Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study |
21 |
| Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study |
21 |
| Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas |
20 |
| Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma |
20 |
| Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis |
20 |
| Targeting the PI3-kinase pathway in triple-negative breast cancer |
20 |
| Latest clinical evidence and further development of PARP inhibitors in ovarian cancer |
20 |
| Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q |
20 |
| Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages |
20 |
| Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy |
20 |
| Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial |
19 |
| Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer |
19 |
| Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study |
19 |
| Overview of current systemic management of EGFR-mutant NSCLC |
19 |
| Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts |
19 |
| BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population |
18 |
| Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients |
18 |
| Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study |
18 |
| Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) |
18 |
| Efficacy of PI3K inhibitors in advanced breast cancer |
18 |
| Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients |
18 |
| Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials |
18 |
| Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA) |
17 |
| Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma |
17 |
| Bevacizumab plus nypofractionated raciotnerapy versus radiotherapy alone in elderly patients with glioblastoma: tie randomized, open-label, phase II ARTE trial |
17 |
| Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information |
17 |
| Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers |
17 |
| Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial |
16 |
| Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review |
16 |
| Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial |
16 |
| Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer |
16 |
| Plasma HPV cell-free DNA monitoring in advances HPV-associates oropharyngeal cancer |
16 |
| Delirium in adult cancer patients: ESMO Clinical Practice Guidelines |
16 |
| Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases |
16 |
| Overview of the relevance of PI3K pathway in HR-positive breast cancer |
16 |
| The European Society for Medical Oncology (ESMO) Precision Medicine Glossary |
16 |
| Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer |
16 |
| Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? |
16 |
| Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) |
16 |
| Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions |
16 |
| Recent advances in circulating nucleic acids in oncology |
15 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) |
15 |
| CMS-dependent prognostic impact of KRAS and BRAF(V600E) mutations in primary colorectal cancer |
15 |
| Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA |
15 |
| Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial |
15 |
| Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial |
15 |
| Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study |
15 |
| Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial |
15 |
| Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution |
15 |
| Are liquid biopsies a surrogate for tissue EGFR testing? |
15 |
| A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors |
14 |
| Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time |
14 |
| Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer |
14 |
| Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium |
14 |
| Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: a systematic review and meta-analyses |
14 |
| A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma |
14 |
| Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines |
14 |
| Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial |
14 |
| nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial |
14 |
| Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue |
14 |
| Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial |
14 |
| Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer |
14 |
| Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer |
14 |
| Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer |
14 |
| Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients |
14 |
| FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer |
14 |
| Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting |
14 |
| Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial |
14 |
